|
Tristel PLC on Thursday said it is seeing ‘strong’ volume momentum underpinned by ‘solid’ growth in the UK and accelerating demand across Europe. The Newmarket, England-based maker of infection prevention products held its annual general meeting on Thursday. Chief Executive Officer Matt Sassone said: ‘I am pleased to report that the company has made a strong start to the new financial year. Trading is in line with expectations and in the first five months we remain firmly on target to deliver revenue growth of at least 10% year-on-year. As in prior years, we expect a greater weighting of revenue and profit contribution in the second half driven by winter seasonal demand across our hospital customer base. ‘We are seeing strong volume momentum, underpinned by solid growth in the UK and accelerating demand across Europe, as customers increasingly adopt our chlorine dioxide technologies and our enhanced commercial execution delivers results. It is pleasing to see increasing demand across Europe, given it is the cornerstone of our international business.’ Further, he added that the company is seeing ‘clear evidence’ in the US of traction and scale-up potential, with Tristel ULT in the first five months of the current financial year that started on July 1, equivalent to the full-year contribution it achieved in financial 2025. Further, Tristel OPH ‘has made an excellent start’ after its launch into the ophthalmology market, CEO Sassone said. Tristel ULT is a disinfectant foam for reprocessing ultrasound probes, while Tristel OPH is a disinfectant foam for reprocessing ophthalmic medical devices. The firm plans to publish interim results in early March. Tristel shares rose 2.4% to 366.00 pence each on Thursday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
